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In this study, attempt is made to establish changes in serum and liver lipoprotein cholesterols accompanying Plasmodium berghei
malarial infection in mice treated with aqueous extract of Ganoderma lucidum at 100, 250, and 500mg/kg body weight in
comparison with 15mg/kg chloroquine (CQ). Significant increases in all the lipoprotein fractions were observed in infected
untreated mice compared with normal control mice. Treatment with 100 and 250mg/kg G. lucidum extract produced significant
reduction in serum total cholesterol (TC) and low-density cholesterol (LDL-C) contents compared with 500mg/kg G. lucidum and
CQ. Treatment with CQ, however, produced significant reduction in hepatic TC and LDL-C compared with the extract. A dose-
dependent significant increase in serum high-density lipoprotein cholesterol (HDL-C) was observed in the G. lucidum treated
mice compared with normal control but significantly lower compared with CQ-treated mice. Liver HDL-C level was significantly
higher in CQ-treated mice compared with normal control and significantly lower compared with G. lucidum-treated and infected
untreated mice. A dose-dependent eﬀect of the extract was observed in both serum and liver very-low density lipoprotein
cholesterol (VLDL-C). The implication of these results is discussed with respect to the parasite survival and proliferation in the
serum and liver.
1. Introduction
The malarial parasite has been observed to have a tremen-
dous requirement for lipids during the replicative stages
that take place in the mammalian host. Biochemical studies
on blood-stage Plasmodium malarial parasites have demon-
strated the parasite’s proficiency at scavenging andmodifying
lipids obtained from the host [1]. Studies have also shown
that the parasites could obtain free fatty acids (FFAs) directly
from the serum or from sources such as high-density
lipoprotein (HDL) [2–4]. Within the parasite, scavenged
phospholipids can be incorporated without modification
[3, 5]. In addition, Plasmodium parasites have the capacity to
modify fatty acids as needed by elongation or desaturation
and incorporate them into phospholipids, diacylglycerols
(DAGs), and triacylglycerols (TAGs) [6, 7].
Indeed, such biochemical revelations have not been
possible for liver-stage parasites because of the diﬃculty
in isolating the parasite from the host hepatocytes and
the low rate of infection during this stage. However, early
studies of malaria in genetically obese Zucker rats (fa/fa) gave
indication that host cell lipids are important for Plasmodium
liver-stage development [8]. These studies demonstrated that
obese Zucker rats, which have hepatocytes with increased
fatty acid synthesis, triglyceridemia and triglyceride content,
supported growth of four times the number of liver-stage
schizonts than their lean counterparts. Additionally, 45 hours
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after infection, schizonts in the obese rats were observed to be
twice the size of those in control rats.
While most scavenged and synthesized lipids are likely
incorporated into the membranes of the rapidly growing
parasite, additional roles for fatty acids remain to be eluci-
dated. For example, studies have yet to identify the source
of fatty acids that are incorporated into GPI, which anchors
numerous proteins, including MSP-1, to the merozoite
plasma membrane. The low expression of MSP-1 in fab
knockout parasites suggests that the FAS-II pathway may
act together with elongases and desaturases to generate the
lipid anchor for some surface proteins, including merozoite
surface protein-1 (MSP-1) [9]. Alternatively, the fatty acid
synthesis type II (FAS-II) pathway activity may provide a
signal for progression to the merozoite formation phase of
intrahepatic development. The specific upregulation of the
FAS-II pathway during the liver stage may allow the parasite
to synthesize its own lipids to supplement those provided by
the host hepatocytes during a particularly explosive period of
growth in the Plasmodium life cycle.
Elucidating stage-specific requirements for import, syn-
thesis, and utilization of fatty acids and lipids in malar-
ial parasite infection is both of considerable promise for
developing novel antimalarial intervention strategies and of
fundamental interest in understanding how these parasites
are so successful in establishing infection in the human host.
Thus, monitoring of serum and liver lipid concentrations
during malarial infection could be of immense contribution
in establishing the parasite source of lipids for its propaga-
tion.
Mushrooms have been known to have medicinal proper-
ties since 1200AD in Chinese folk medicine [10]. In recent
years there has been renewed interest in cholesterol lowering
properties of mushrooms, including Ganoderma lucidum
(Reishi mushroom) [11, 12], Pleurotus ostreatus (Oyster
mushroom) [13], and Agaricus bisporus (champignon) [14].
In this study, our focus is G. lucidum, an important medicinal
fungus belonging to the Ganodermataceae family that has
been studied for its many interesting health promoting prop-
erties, including antitumour, anti-inflammatory, antiplatelet
aggregation, antidiabetic, and hypocholesterolemic proper-
ties [15–19]. The cholesterol lowering property of G. lucidum
is explored in this study for its possible eﬀects in preventing
the proliferation of malarial parasites in mice.
2. Materials and Methods
2.1. Fungal Materials. Fruiting bodies of G. lucidum were
obtained locally from open forest at Ipele in Ose Local Gov-
ernment Area of Ondo State, Nigeria. The fungal material
was identified by Dr. S. Fakoya of the Department of Biolog-
ical Sciences, Joseph Ayo Babalola University, Ikeji-Arakeji,
Osun State, Nigeria, where voucher specimen number 1103
has been deposited.
2.2. Extract Preparation. Fruiting bodies of G. lucidum were
sorted, washed to remove debris and dust particles, and then
dried under shade for two weeks. The dried materials were
cut into pieces and ground into powder using mechanical
grinder. The powdered sample was kept in airtight container
and stored at 4◦C until required for further analysis. One
hundred gram (100 g) of the powdered fungal material was
soaked in 1000mL distilled water and placed in an orbital
shaker at room temperature for 48 hr. The aqueous extract
was filtered with a muslin cloth. The resulting filtrate was
evaporated to dryness at 37◦C by the help of a Speed Vac
(Model 7811001, Labconco, USA). The recovered extract
was weighed and formulated in distilled water to give the
required dose.
2.3. Animals and Treatment. A total of forty-eight (48)
male Swiss albino mice (15–22 g body weight) obtained
from the animal laboratory of the Department of Medical
Biochemistry, University of Ibadan, Nigeria were used for
the study. The animals were housed in stainless steel cages
with raised wired floor at 30◦C under standard conditions of
humidity and 12 h light/dark cycle. They were fed standard
feed (Guinea Feeds Ltd) and water ad libitum. The animals
were kept for an initial period of two feed to acclimatize
with their new environment. Before the commencement of
the experiment animals were fasted overnight (but allowed
access to water ad libitum) and weighed. All experimental
protocols complied with NIH guidelines [20].
2.4. Malarial Parasite. Chloroquine sensitive Plasmodium
berghei berghei (NK-65) obtained from the Institute for
Advanced Medical Research and Training (IMRAT), Uni-
versity College Hospital, University of Ibadan, Nigeria, and
kept at the Department of Biochemistry, Joseph Ayo Babalola
University, Ikeji-Arakeji, was used for the study. The parasite
was subsequently maintained in our laboratory by serial
blood passage from mouse to mouse [21] every four days.
2.5. Inoculums. One milliliter parasitized erythrocytes were
obtained from a donor-infected mouse by cardiac puncture
in heparin and made up to 5mL with normal saline.
Mice were inoculated intraperitoneally with 0.2mL blood
suspension containing 106–107 parasitized erythrocytes on
day zero. Infected mice with parasitemia of 10–12% were
allocated to five groups. The fungal extract and the standard
drug (CQ) administration were carried out for four days
postinfection.
2.6. Treatment Regimen. Forty-eight mice (consisting of 40
infected divided into five groups of eight animals each; a
sixth group of eight normal mice, as positive control) were
used for this study. The four day postinfection treatment
commenced at the establishment of parasitemia in the mice.
The treatment administered to each group is as follows:
(i) negative control—infected mice treated with 0.2mL
normal saline;
(ii) extract test group I (AQ100)—infected mice treated
with 100mg/kg G. lucidum aqueous extract;
(iii) extract test group II (AQ250)—infected mice treated
with 250mg/kg G. lucidum aqueous extract;
(iv) extract test group III (AQ500)—infected mice treated
with 500mg/kg G. lucidum aqueous extract;
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(v) reference test group (CQ)—Infected mice treated
with 15mg/kg chloroquine phosphate;
(vi) positive control—normal mice treated with 0.2mL
distilled water.
Treatments were given once daily by gavage using
intubator for four consecutive days according to the method
of Builders et al. [22]. On the fifth day (postinfection) thick
smears of blood films were obtained from the peripheral
blood on the tail from each mouse and used in the
determination of the suppressive eﬀect of the extract on
the parasitemia level. Thereafter, extract and drug treatment
were stopped while mice in each group were placed under
surveillance until signs of death were noticed in the infected
untreated group (negative control) after which mice in each
group were sacrificed.
2.7. Blood Collection and Serum Preparation. As soon as
signs of death were noticed in the infected untreated mice
group (negative control) mice in each group were weighed
anesthetized (in chloroform saturated chamber) and sacri-
ficed by jugular puncture. Blood was obtained through their
jugular vein into plain sterile bottles and allowed to clot
for 2 h and then centrifuged at 3,000×g for ten minutes at
room temperature to obtain the sera. The sera samples were
collected by aspiration using a pasture pipette into sterile
bijou bottles and stored frozen until required for analysis,
which was done within 72 h.
2.8. Tissue Preparation. Upon sacrifice, liver and kidneys of
each mouse were quickly excised, rinsed in normal saline,
blotted dry on tissue paper, and weighed. Each tissue was
placed in separate plastic vial containing ice-cold normal
saline and stored at −8◦C until required for further analysis.
2.9. Preparation of Tissue Homogenate. A weighed portion
of liver and kidneys of each mouse was cut out, chopped
into small pieces and homogenized using precooled pestle
and mortar in a bowl of ice cubes. A 5% homogenate of
each tissue was obtained in buﬀer solution (50mM Tris-
HCl) using normal saline solution, and stored at −8◦C until
further analysis was carried out.
2.10. Assays. Total cholesterol (TC), low-density lipoprotein
(LDL) cholesterol, and high-density lipoprotein (HDL)
cholesterol were determined using commercial kits (Randox
Laboratory Ltd., UK) following the manufacturer’s instruc-
tion while very low-density lipoprotein (VLDL) cholesterol
concentration was determined by diﬀerence.
2.11. Statistical Analysis. Results presented are means± SEM
of eight independent determinations. Results obtained from
this study were statistically analyzed using one way analysis
of variance (ANOVA) and Duncan’s Multiple Range Test
(DMRT) using SPSS 17.0. Significant diﬀerences between the
treatment means were determined at 95% confidence level.
3. Results
The eﬀects of the extracts treatment compared with CQ
and SP as reference drugs on percentage suppression and
mean survival time are presented in Table 1. There was no
significant diﬀerence in % suppression observed in mice
treated with 100mg/kg and those treated with 250mg/kg
aqueous extract and aqueous 200 and aqueous 500 groups,
though a significant decrease was noticed in % suppression
on comparing aqueous 100 and aqueous 500 treated groups.
From Table 2, serum cholesterol fractions (TC, LDL,
HDL, and VLDL) were observed to be significantly elevated
(P < 0.01) above normal control level in the infected
control mice and infected mice treated with CQ (Table 1).
However, significant decreases (P < 0.05) were observed in
serum TC, LDL, HDL, and VLDL levels in infected mice
treated with aqueous extract of Ganoderma lucidum (at
100, 250 and 500mg/kg body weight) compared to infected
untreated mice though these values were significantly higher
compared to normal control level. Serum TC and LDL-C
concentrations were not significantly (P > 0.05) changed in
mice treated with 100mg/kg and 250mg/kg body weight of
the extract. The extract at 100mg/kg and 250mg/kg body
weight produced significantly lower reductions in serum TC
and LDL-C compared to 500mg/kg extract concentration.
As shown in Table 3, liver TC, LDL-C, HDL-C, and
VLDL-C concentrations were significantly (P < 0.01) higher
in infected control mice compared with normal control.
The liver concentration of these cholesterol fractions were
significantly (P < 0.05) reduced in P. berghei infection as
a result of treatment with aqueous extract of G. lucidum.
Liver TC, LDL, HDL and VLDL cholesterol were significantly
(P < 0.05) higher in infected mice treated with 100, 250,
and 500mg/kg body weight G. lucidum aqueous extract
compared to those administered CQ.
4. Discussion
Lipids have been observed to play important roles in
pathological changes observed in disease conditions and are
implicated in the production of immunity against diseases
[23]. Serum lipids primarily bound to lipoproteins can
be elevated by an increase in biosynthesis and/or by a
decrease in their removal. Both of these processes appear to
contribute to the hyperlipidemia that is often produced by
some pathological changes. Although the source of increase
in erythrocyte lipid component in malaria infection is not
from lipid of the parasite there is no indication that the
increase in the serum lipid is due to the lipid content of the
parasite [24].
The results obtained from the suppressive, curative, and
prophylactic tests indicate that the aqueous, chloroform
and ethanol extracts of G. lucidum possessed significant
antiplasmodial activity as evident from the chemosuppres-
sion obtained during the four day early infection test.
However, on established infection the plant extracts also
exhibited significant activity as evident from the curative
eﬀect of the extracts. Agents with suppressive activity against
Plasmodium berghei were known for antimalarial activity
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Table 1: Suppressive eﬀect of aqueous extract of Ganoderma lucidum on parasitemia in mice infected with Plasmodium berghei.
Treatment groups Parasite count % suppression
Controls
Normal (P-CTR) — —
Infected (N-CTR) 31.10 ± 1.20 —
Aqueous extract
AQ100 14.20 ± 0.60 54.20 ± 3.70a
AQ250 17.40 ± 1.20 43.82 ± 6.03a,b
AQ500 19.40 ± 0.90 37.42 ± 5.31b,c
Reference drug CQ 2.25 ± 0.85 93.65 ± 0.47c
Results are means ± SEM of eight independent determinations. Values in the same row carrying diﬀerent superscripts are significant (P < 0.05) from each
other.
Note. AQ100: infected mice treated with 100mg/kg aqueous extract; AQ250: infected mice treated with 250mg/kg aqueous extract; AQ500: infected mice treated
with 500 mg/kg aqueous extract; CQ: infected mice treated with chloroquine.
Table 2: Serum TC, LDL-, HDL-, and VLDL-cholesterol levels in mice Plasmodium berghei infected mice treated with aqueous extract of
Ganoderma lucidum.
Treatment groups TC LDL HDL VLDL
Controls
Normal 8.75 ± 0.86a 5.29 ± 0.57a 1.46 ± 0.01a 2.01 ± 0.01a
Infected 68.43 ± 5.33b 36.56 ± 5.64b 16.14 ± 0.01b 15.74 ± 0.01b
Aqueous extract
AQ100 33.76 ± 2.27c 21.77 ± 1.47c 3.88 ± 0.01c 8.10 ± 0.17c
AQ250 39.97 ± 1.29c 25.58 ± 0.83c 4.40 ± 0.01d 9.99 ± 0.06d
AQ500 63.87 ± 5.03b 40.87 ± 3.22b 8.33 ± 0.01e 14.69 ± 0.01e
Reference drug CQ 66.17 ± 4.50b 39.86 ± 2.40b 10.43 ± 0.01f 15.88 ± 0.02b
Results are means ± SEM of eight independent determinations. Values in the same row carrying diﬀerent superscripts are significant (P < 0.05) from each
other.
Note. P-CTR: positive control mice; N-CTR: negative control mice; AQ100: infected group treated with 100mg/kg G. lucidum; AQ250: infected group treated
with 250mg/kg G. lucidum; AQ500: infected mice treated with 500mg/kg G. lucidum; CQ: infected mice treated with chloroquine.
Table 3: Liver TC, LDL-, HDL-, and VLDL-cholesterol levels in Plasmodium berghei-infected mice treated with aqueous extract of
Ganoderma lucidum.
Treatment groups TC LDL HDL VLDL
Controls
Normal 66.03 ± 6.97a 37.51 ± 3.82a 12.67 ± 0.01a 15.85 ± 0.06a
Infected 171.78 ± 8.70b 99.25 ± 8.46b 31.31 ± 0.01b 41.22 ± 0.02b
Aqueous extract
AQ100 146.42 ± 4.34c 93.70 ± 2.78b 19.29 ± 0.25c 33.68 ± 0.02c
AQ250 150.94 ± 9.54b,c 96.60 ± 6.10b 16.60 ± 0.11d 37.74 ± 0.02d
AQ500 172.00 ± 8.35b 110.08 ± 5.34b 22.36 ± 0.01e 39.56 ± 0.06e
Reference drug CQ 111.56 ± 4.99d 71.40 ± 3.19c 13.39 ± 0.01f 26.78 ± 0.02f
Results are means ± SEM of eight independent determinations. Values in the same row carrying diﬀerent superscripts are significant (P < 0.05) from each
other.
Note. P-CTR: positive control mice; N-CTR: negative control mice; AQ100: infected group treated with 100mg/kg G. lucidum; AQ250: infected group treated
with 250mg/kg G. lucidum; AQ500: infected mice treated with 500mg/kg G. lucidum; CQ: infected mice treated with chloroquine.
[21]. It is noteworthy that the antiplasmodial activity of the
extract at all doses during early and established infections
was comparable to that of the standard drug, CQ. There was a
dose-dependent chemosuppression of parasitemia seen with
the extract. In infected untreated mice, the parasite count
increased daily until the death of the animals which was also
observed in other studies [25, 26].
It is evident based on the findings from this study that
aqueous extract of the fruiting bodies of G. lucidum represent
potential antiplsmodial agent. The activity (antiplasmodial)
may be attributed to terpenes, sterols, and flavonoids present
in the extract as confirmed in this study. Antiplasmodial
screening of plant substances has implicated terpenes,
flavonoids and alkaloids [27–29]. These compounds could
be acting singly or in synergy with one another to exert the
antiplasmodial activity observed in this study.
Results obtained in the present study show significant
increases in serum and liver total, LDL, VLDL, and HDL
cholesterol in mice infected with Plasmodium berghei. This
observation is consistent with reports from earlier studies by
Onyeneke et al. [30] and Onongbu and Onyeneke [31] which
showed increased serum lipoprotein fractions in malarial
patients compared with apparently healthy control subjects.
The observed increases in hepatic lipoproteins content are
also in agreement with the report of Lombard et al. [8].
According to Lombard et al. [8] increase in hepatic lipid
in malarial subjects is consistent with the degree of para-
sitemia. Again, observations from the present study support
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this assertion as the level of parasitemia correlates with
hepatic lipoprotein composition.
As observed from this study, administration of aqueous
extract of G. lucidum downregulates serum and liver lipopro-
tein content. The observed eﬀect of the extract was to be
negatively correlated with parasitemia level. The hypocholes-
terolemic property of G. lucidum has been established in our
earlier study [19].
Malaria disturbs liver function though there is no
evidence of hepatic insuﬃciency. In malarial infection, the
liver is commonly enlarged and congested with parasitized
red cells in sinusoids and centrilobular veins and swollen
parenchymatous and kupﬀer cells [32]. Lipid metabolism
is therefore deranged and the resulting lipoprotein particles
synthesized by the liver undergo drastic changes in composi-
tion. Maurois et al. [33] have demonstrated that increased
lipolysis induced by threshold of parasitemia promotes
VLDL synthesis and their metabolism into LDL. Thus, with
increase in parasitemia there was a progressive increase
in LDL fraction and with the resulting incorporation of
cholesterol particles, the overall LDL cholesterol was found
to be increased. There is also the possibility of a reduction
in the breakdown of LDL by the infective liver tissue thereby
leading to an increase in these particles. It is also likely that
the elevation in LDL cholesterol may be due to decrease
uptake by the infected erythrocytes as a result of increased
levels of parasitemia.
In conclusion, results obtained from this study show
that aqueous extract of G. lucidum reduces serum and liver
lipoprotein cholesterol with a corresponding decrease in
parasitemia levels in both tissues. Therefore, it could thus be
inferred that the antimalarial property of the extract could
possibly be mediated by mechanisms involving reduction in
liver lipids.
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